Antibiotics of the future: are they prone to bacterial resistance?

This project aims to develop a forecasting framework for the long-term effectiveness of new antibiotics by studying bacterial resistance evolution and its implications for future antibiotic design and use.

Subsidie
€ 3.479.716
2024

Projectdetails

Introduction

Although several new antibiotic candidates are in the clinical pipeline, the future evolution of resistance in bacteria may render them ineffective. This project aims to develop a framework for forecasting the long-term effectiveness of new antibiotic candidates.

Objectives

For this purpose, we will decipher the general principles shaping bacterial resistance to a wide range of antibiotic candidates currently in development. Using recently developed methods in our laboratory, we will study resistance evolution in bacterial ESKAPE pathogens at unprecedented resolution and address four specific aims:

  1. Shared Features of Antibiotics
    We explore the shared features of antibiotics with limited susceptibility to resistance.

  2. Species-Specific Differences
    We systematically map species-specific differences in resistance evolution with implications on narrow-spectrum antibacterial therapies that could remain effective.

  3. Clinical Risks Associated with Resistance
    We assess the clinical risks associated with resistance by studying the global biogeography and habitat-specificity of resistant bacteria.

  4. Links Between Resistance Evolution and Virulence
    Finally, we systematically explore the potential links between resistance evolution and increased bacterial virulence.

Expected Outcomes

The outcomes will provide guidelines for future antibiotic use, aid in genomic surveillance of resistance genes, and facilitate the design of antibiotics with reduced susceptibility to resistance.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 3.479.716
Totale projectbegroting€ 3.479.716

Tijdlijn

Startdatum1-7-2024
Einddatum30-6-2029
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • HUN-REN SZEGEDI BIOLOGIAI KUTATOKOZPONTpenvoerder

Land(en)

Hungary

Vergelijkbare projecten binnen European Research Council

ERC STG

MANUNKIND: Determinants and Dynamics of Collaborative Exploitation

This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.

€ 1.497.749
ERC STG

Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure

The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.

€ 1.498.280
ERC STG

Uncovering the mechanisms of action of an antiviral bacterium

This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.

€ 1.500.000
ERC STG

The Ethics of Loneliness and Sociability

This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.

€ 1.025.860

Vergelijkbare projecten uit andere regelingen

ERC COG

Exploiting plasmid–bacteria interactions to fight the evolution of antimicrobial resistance

PLAS-FIGHTER aims to develop innovative strategies against plasmid-mediated antimicrobial resistance by exploring plasmid-induced physiological effects in bacteria using advanced screening and ecological models.

€ 1.999.573
ERC SyG

Deep learning analysis of imaging and metabolomic data to accelerate antibiotic discovery against antimicrobial resistance

AI4AMR aims to revolutionize antibiotic discovery by using advanced AI and multi-dimensional data analysis to identify novel antibiotics and their mechanisms of action against antimicrobial resistance.

€ 10.968.734
MIT Haalbaarheid

InnomABs

ImmunoPrecise Antibodies (IPA) onderzoekt de haalbaarheid van het ontwikkelen van menselijke eiwitten (biologicals) als alternatief voor antibiotica om antimicrobiële resistentie te bestrijden.

€ 14.888
MIT Haalbaarheid

Behandeling van antibioticaresistente S. aureus en preventie van verdere antibioticaresistentie

Het project onderzoekt de haalbaarheid van een op antilichamen gebaseerd product voor de behandeling van S. aureus-infecties, gericht op genezing en het voorkomen van antibioticaresistentie.

€ 20.000